| Walgreens #11300 | |
| 623 S Burlington Blvd, Burlington, Washington 98233 | |
| (360) 707-2741 |
| Name | Walgreens #11300 |
|---|---|
| Organization Name | Walgreen Co |
| Location | 623 S Burlington Blvd, Burlington, Washington 98233 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (360) 707-2741 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
Even a modest one percent reduction in mortality from cancer would be worth nearly $500 billion in social value, according to a new study by economists Kevin Murphy and Robert Topel of the University of Chicago Graduate School of Business.
Pharma major, Lupin Ltd announced today that it has received official communication from the US FDA on the satisfactory resolution of the Warning Letter issued earlier to its Mandideep site. The company had received a Warning letter for its Mandideep site in May 2009. In the ensuing seven months, the company made significant enhancements and took appropriate corrective actions.
Even 30 minutes of exercise per week has the potential to significantly reduce a woman's risk of developing cervical cancer, according to a study from scientists at Roswell Park Cancer Institute (RPCI). The case-control study was recently published in the Journal of Lower Genital Tract Disease.
› Verified 3 days ago
| NPI Number | 1639471386 |
| Organization Name | WALGREEN CO |
| Doing Business As | WALGREENS #11300 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 623 S Burlington Blvd, Burlington, WA 98233 |
| Phone Number | 360-707-2741 |
News Archive
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
Even a modest one percent reduction in mortality from cancer would be worth nearly $500 billion in social value, according to a new study by economists Kevin Murphy and Robert Topel of the University of Chicago Graduate School of Business.
Pharma major, Lupin Ltd announced today that it has received official communication from the US FDA on the satisfactory resolution of the Warning Letter issued earlier to its Mandideep site. The company had received a Warning letter for its Mandideep site in May 2009. In the ensuing seven months, the company made significant enhancements and took appropriate corrective actions.
Even 30 minutes of exercise per week has the potential to significantly reduce a woman's risk of developing cervical cancer, according to a study from scientists at Roswell Park Cancer Institute (RPCI). The case-control study was recently published in the Journal of Lower Genital Tract Disease.
› Verified 3 days ago
News Archive
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
Even a modest one percent reduction in mortality from cancer would be worth nearly $500 billion in social value, according to a new study by economists Kevin Murphy and Robert Topel of the University of Chicago Graduate School of Business.
Pharma major, Lupin Ltd announced today that it has received official communication from the US FDA on the satisfactory resolution of the Warning Letter issued earlier to its Mandideep site. The company had received a Warning letter for its Mandideep site in May 2009. In the ensuing seven months, the company made significant enhancements and took appropriate corrective actions.
Even 30 minutes of exercise per week has the potential to significantly reduce a woman's risk of developing cervical cancer, according to a study from scientists at Roswell Park Cancer Institute (RPCI). The case-control study was recently published in the Journal of Lower Genital Tract Disease.
› Verified 3 days ago
Fred Meyer Pharmacy #024 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 920 S Burlington Blvd, Burlington, Washington 98233 Phone: (360) 757-9100 | |
Haggen Pharmacy #3436 Type: Pharmacy Location: 757 Haggen Dr, Burlington, Washington 98233 Phone: (360) 814-1561 | |
Walgreens #11300 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 623 S Burlington Blvd, Burlington, Washington 98233 Phone: (360) 707-2741 |